Answers are grounded in this paper and cite their sources.
Review examines B cell contributions to graft-versus-leukaemia responses, suggesting new therapeutic insights.
For many high-risk haematologic malignancies, such as acute myeloid leukaemia, the success of therapy relies mainly on invoking a curative antitumour immune response. This can be achieved by inducing a graft-versus-leukaemia response following allogeneic haematopoietic cell transplantation. While the contribution of T cells and natural killer cells to graft-versus-leukaemia responses is established, the contribution of B cells and antibodies is relatively unexplored. This article reviews what is known about the contribution of B cells and tumour-specific antibody responses to a successful graft-versus-leukaemia response leading to eradication of the tumour.
No takes yet. Share an insight, caveat, or question.
Jong et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: